BG66517B1 - Супресор на ендогенния човешки гама - интерферон - Google Patents

Супресор на ендогенния човешки гама - интерферон

Info

Publication number
BG66517B1
BG66517B1 BG110103A BG11010308A BG66517B1 BG 66517 B1 BG66517 B1 BG 66517B1 BG 110103 A BG110103 A BG 110103A BG 11010308 A BG11010308 A BG 11010308A BG 66517 B1 BG66517 B1 BG 66517B1
Authority
BG
Bulgaria
Prior art keywords
gamma
inhibitor
endogenous human
human interferon
hifn
Prior art date
Application number
BG110103A
Other languages
English (en)
Other versions
BG110103A (bg
Inventor
Иван Иванов
Hans-Guenther Grigoleit
Геновева НАЧЕВА
Стефан ПЕТРОВ
Original Assignee
Tigo Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigo Gmbh filed Critical Tigo Gmbh
Priority to BG110103A priority Critical patent/BG66517B1/bg
Priority to PCT/BG2008/000025 priority patent/WO2009124362A1/en
Priority to US12/735,882 priority patent/US20110135602A1/en
Priority to EP08873818.2A priority patent/EP2274326B1/en
Publication of BG110103A publication Critical patent/BG110103A/bg
Priority to US14/243,861 priority patent/US9359421B2/en
Publication of BG66517B1 publication Critical patent/BG66517B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до cyпреcop на ендогенния човешки гама-интерферон (hIFN-гама), приложим при автоимунни заболявания и при използване на алотрансплантанти. По своята същност супресорът представлява генно-модифицирани варианти на hIFN-гама, при които в гена на IFN-гама са въведени точкови мутации, водещи до замяна на аминокиселините в позиции 86, 87 и 88 в областта, участваща в сигналната трансдукция.@
BG110103A 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон BG66517B1 (bg)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон
PCT/BG2008/000025 WO2009124362A1 (en) 2008-04-08 2008-12-02 Suppressor of the endogenous interferon- gamma
US12/735,882 US20110135602A1 (en) 2008-04-08 2008-12-02 Supperssor of the endogenous interferon-gamma
EP08873818.2A EP2274326B1 (en) 2008-04-08 2008-12-02 Suppressor of the endogenous interferon- gamma
US14/243,861 US9359421B2 (en) 2008-04-08 2014-04-02 Suppressor of the endogenous interferon-gamma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон

Publications (2)

Publication Number Publication Date
BG110103A BG110103A (bg) 2009-10-30
BG66517B1 true BG66517B1 (bg) 2016-02-29

Family

ID=41161478

Family Applications (1)

Application Number Title Priority Date Filing Date
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон

Country Status (4)

Country Link
US (1) US20110135602A1 (bg)
EP (1) EP2274326B1 (bg)
BG (1) BG66517B1 (bg)
WO (1) WO2009124362A1 (bg)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211852A4 (en) * 2007-10-18 2013-10-16 Univ Yale COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION
US20100016262A1 (en) * 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
US9415046B2 (en) * 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
AT393690B (de) 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
BG52073B2 (en) 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
ZA952797B (en) 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
WO1995030435A2 (en) 1994-05-10 1995-11-16 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
RU2073522C1 (ru) 1995-07-20 1997-02-20 Олег Васильевич Рубальский Лекарственный препарат противовирусного действия
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
WO2001045747A1 (en) 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
AUPP823999A0 (en) 1999-01-20 1999-02-11 University Of Queensland, The A treatment
RU2268749C2 (ru) * 1999-11-12 2006-01-27 Максиджен Холдингз Лтд КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
RU2187332C1 (ru) 2000-12-18 2002-08-20 Гапонюк Петр Яковлевич Лечебное средство
HUP0303645A3 (en) 2001-04-06 2005-12-28 Maxygen Holdings Ltd Georgetow Interferon gamma polypeptide variants
CA2463935A1 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
KR20080019606A (ko) * 2005-05-04 2008-03-04 나우틸루스 바이오텍 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법

Also Published As

Publication number Publication date
BG110103A (bg) 2009-10-30
WO2009124362A1 (en) 2009-10-15
EP2274326A1 (en) 2011-01-19
EP2274326B1 (en) 2014-01-01
US20110135602A1 (en) 2011-06-09
EP2274326A4 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
NZ576467A (en) Smoothened polypeptides and methods of use
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
TW200613551A (en) A polypeptide having a ω3 fatty acid desaturation activity, a polynucleotide for coding the same, and use thereof
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
GEP20146056B (en) Acylated glucagon analogues
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
ZA200900379B (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
TN2012000303A1 (en) Oxyntomodulin peptide analogue
UA94221C2 (en) Lipocalin protein
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
IN2014CN00414A (bg)
TW200603798A (en) Disalt inhibitors of il-12 production
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
UA115979C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-3-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
BG66517B1 (bg) Супресор на ендогенния човешки гама - интерферон
EP2029754A4 (en) MAGNETOSOME GENE EXPRESSION IN EUKARYONTIC CELLS
MX354302B (es) Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.
MY155568A (en) Oral care methods and systems
TW200602062A (en) Improved formulations of 6-mercaptopurine
UA95446C2 (ru) Мутаци в генах oas1